A Growing Question as Cannabis Becomes More Accessible
As cannabis legalization spreads and more people use marijuana for both recreational and therapeutic purposes, ketamine therapy patients increasingly want to know: can I use cannabis alongside my treatment? The answer is more nuanced than a simple yes or no, and the research — while still limited — offers useful guidance. For context on other substance interactions, see our guides on ketamine and alcohol and ketamine with other medications.
What We Know About the Interaction
Ketamine and cannabis affect the brain through different primary mechanisms. Ketamine acts mainly on the glutamate system via NMDA receptor antagonism, while cannabis operates primarily through the endocannabinoid system via CB1 and CB2 receptors. Despite targeting different systems, there is meaningful overlap in their effects, and the interaction between these two substances is an active area of study.
Overlapping Effects
Both ketamine and cannabis can produce:
- Altered perception and dissociation. Ketamine's dissociative effects are well-documented, and THC (the primary psychoactive component of cannabis) can also alter perception and sense of self. Together, these effects may be amplified in unpredictable ways.
- Changes in heart rate and blood pressure. Ketamine typically raises both, while cannabis can raise heart rate but has variable effects on blood pressure. The combined cardiovascular load is a consideration, particularly for patients with cardiac risk factors.
- Anxiety modulation. Both substances can either reduce or increase anxiety depending on dose, strain (in the case of cannabis), individual biology, and context. The combination may produce unexpected anxiety or paranoia in some patients.
- Sedation. Both can produce drowsiness and impaired motor function, and these effects may compound when used together.
Potential Neuroplasticity Concerns
One of the more important considerations is how cannabis may affect the neuroplastic processes that ketamine initiates. Early research suggests that chronic heavy cannabis use may impair certain aspects of neuroplasticity, particularly in the hippocampus — a brain region critical for mood regulation and memory. If cannabis is blunting the neuroplastic response that ketamine triggers, it could reduce treatment effectiveness.
However, this research is preliminary, and the picture is complicated by the fact that cannabis contains dozens of active compounds beyond THC. CBD (cannabidiol), for example, has shown neuroprotective properties in some studies and does not appear to carry the same plasticity concerns as THC.
What Providers Generally Recommend
Because large-scale clinical trials examining the ketamine-cannabis interaction do not yet exist, provider recommendations are based on clinical experience, pharmacological principles, and the limited available research. Here is what most providers advise:
On session days:
- Do not use cannabis before a ketamine session. THC in your system can alter the ketamine experience unpredictably and may increase the risk of anxiety, nausea, or cardiovascular complications.
- Avoid cannabis for at least 12 to 24 hours before treatment.
- Do not use cannabis while any effects from the ketamine session are still present.
After sessions:
- Most providers recommend waiting at least 24 hours after a ketamine session before using cannabis.
- The neuroplastic window (24 to 72 hours post-session) is when your brain is most actively forming new connections. Some providers suggest avoiding cannabis during this entire period to give integration the best chance of working.
Between sessions:
- Occasional, moderate cannabis use between sessions is generally considered lower risk than use close to treatment times.
- Heavy daily use is more concerning from both an efficacy and safety standpoint.
- CBD-only products are viewed more favorably by most providers than THC-dominant products.
THC vs. CBD: An Important Distinction
Not all cannabis products are equivalent when it comes to ketamine therapy interactions.
THC (tetrahydrocannabinol) is the psychoactive compound responsible for the "high." It is the component most likely to interact with ketamine's effects on perception, anxiety, and potentially neuroplasticity. THC is the primary concern when providers discuss cannabis and ketamine.
CBD (cannabidiol) does not produce intoxication and has a different pharmacological profile. Some research suggests CBD may have anxiolytic (anxiety-reducing) and anti-inflammatory properties without the cognitive impairment associated with THC. Many providers are more comfortable with patients using CBD products, though recommendations vary.
Edibles vs. smoking or vaping also matters. Edibles produce delayed, longer-lasting, and often stronger effects that are harder to control. Inhaled cannabis offers faster onset and shorter duration, which makes accidental overlap with ketamine sessions less likely if proper timing is observed.
Medical Cannabis Patients
If you use cannabis under medical supervision for chronic pain, seizures, nausea, or other conditions, the conversation with your ketamine provider becomes especially important. Abruptly stopping a medication that is managing active symptoms is not always advisable, and your provider needs to weigh the benefits of your cannabis prescription against any potential interaction with ketamine therapy.
Be forthcoming about:
- What you use (THC content, CBD content, form factor)
- How often and how much you use
- What condition it is treating
- Whether you have noticed any interaction between your cannabis use and your ketamine treatment response
This information allows your provider to make informed recommendations specific to your situation rather than applying blanket guidelines.
What the Research Shows
The clinical evidence specifically examining ketamine-cannabis interactions is limited but growing:
- A 2021 study examining cannabis use among ketamine therapy patients found that active cannabis users did not show significantly different acute responses to ketamine infusions but had shorter duration of antidepressant benefit compared to non-users.
- Animal studies have shown that cannabinoid and glutamate systems interact in complex ways, with some evidence that chronic THC exposure alters NMDA receptor expression — the very receptors ketamine targets.
- Case reports have described increased dissociation and anxiety when cannabis was used close to ketamine sessions, though these are anecdotal and not controlled studies.
Practical Recommendations
Based on the available evidence and clinical consensus:
- Disclose your cannabis use honestly to your ketamine provider. This is medical information, not a moral judgment.
- Observe timing guidelines — avoid cannabis for 24 hours before and after sessions at minimum.
- Consider reducing or pausing cannabis use during the active treatment phase (loading doses) when maximizing neuroplasticity is most critical.
- If you use cannabis for sleep or pain, discuss alternative strategies with your provider for the periods when you need to abstain.
- Track your response carefully. If you notice that cannabis use between sessions correlates with reduced treatment benefit, share this observation with your provider.
- If you choose to use cannabis between sessions, lower-THC and higher-CBD products used in moderation are generally considered the lower-risk option.
The Evolving Picture
As both ketamine therapy and cannabis research advance, our understanding of their interaction will become clearer. For now, a cautious approach that prioritizes the effectiveness of your ketamine treatment is wise. The investment you are making in ketamine therapy — financially, emotionally, and in terms of hope — deserves the best possible conditions for success.
References
- Cannabinoid-Glutamate Interactions in the Brain — Research on how the endocannabinoid system modulates glutamatergic neurotransmission relevant to ketamine's mechanism of action
- Cannabis Use and Mental Health Treatment Outcomes — NIH review examining how cannabis use affects outcomes in various psychiatric treatments
- Effects of Cannabinoids on Neuroplasticity — Investigation of how THC and CBD differentially affect brain plasticity mechanisms